Business
Theralase Technologies Awarded 2020 TSX Venture 50
TORONTO, ON / ACCESSWIRE / February 20, 2020 / Theralase ® Technologies Inc. (" Ther...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Technologies Awarded 2020 TSX Venture 50TORONTO, ON / ACCESSWIRE / February 20, 2020 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and associated drug formulations, is pleased to announce today that Theralase has been named a 2020 TSX Venture 50™ company.Presented by the TSX Venture Exchange, Theralase is ranked number eight in the Clean Technology & Life Sciences sector. This award recognizes the top 10 performing companies from five industry sectors selected based on three equally weighted criteria: market capitalization growth, share price appreciation and trading volume amount. Theralase was previously named a TSX Venture 50™ company in 2015 & 2019 making this the third year Theralase has been recognized as a top performer in the Clean Technology & Life Sciences sector.On February 21, 2020, Theralase will be ringing the market opening bell with all the other TSX Venture 50™ companies at the Toronto Stock Exchange.Shawn Shirazi, Ph.D., CEO of Theralase stated that \"It is an honour to be recognized as an elite company on the TSX Venture for the third year. This achievement is a strong demonstration of the value that the Company has delivered to shareholders the preceding year. In 2019, Theralase reached a new milestone where a single treatment from Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study has achieved \"cancer free\" status, a complete response to treatment, at 18 months post treatment at therapeutic dose of TLD-1433 in 67% of patients presenting with Bacillus Calmette Guerin (\"BCG\")-Unresponsive NMIBC. Additionally, the Pivotal Phase II NMIBC clinical study has been rapidly progressing in Canada with 10 patients treated, to date, surpassing the expected enrollment timeline. We will continue to go above and beyond, reaching new milestones this year.\"Please click the link to see TSX Venture 50™ interview with CEO of Theralase, Shawn Shirazi: https://vimeo.com/390258555/85c35c6967. For more information, visit: www.tsx.com/venture50About Study IIThe Phase II NMIBC Clinical Study utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433, focusing on the treatment of ap...